In addition, Winship et al. [46, 47] reported that therapeutically targeting IL11 Receptor-α could effectively inhibit endometrial cancer growth and dissemination by reducing STAT3 phosphorylation. This evidence concerns the gene STAT3 and endometrial cancer.